189 related articles for article (PubMed ID: 18485768)
1. Modeling the binding modes of Kv1.5 potassium channel and blockers.
Yang Q; Du L; Wang X; Li M; You Q
J Mol Graph Model; 2008 Sep; 27(2):178-87. PubMed ID: 18485768
[TBL] [Abstract][Full Text] [Related]
2. Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels.
Eldstrom J; Fedida D
J Mol Graph Model; 2009 Oct; 28(3):226-35. PubMed ID: 19713139
[TBL] [Abstract][Full Text] [Related]
3. The discovery of Kv1.5 blockers as a case study for the application of virtual screening approaches.
Pirard B; Brendel J; Peukert S
J Chem Inf Model; 2005; 45(2):477-85. PubMed ID: 15807513
[TBL] [Abstract][Full Text] [Related]
4. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels.
Eldstrom J; Wang Z; Xu H; Pourrier M; Ezrin A; Gibson K; Fedida D
Mol Pharmacol; 2007 Dec; 72(6):1522-34. PubMed ID: 17872968
[TBL] [Abstract][Full Text] [Related]
5. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.
Ford JW; Milnes JT
J Cardiovasc Pharmacol; 2008 Aug; 52(2):105-20. PubMed ID: 18670369
[TBL] [Abstract][Full Text] [Related]
6. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
Blass BE; Coburn K; Lee W; Fairweather N; Fluxe A; Wu S; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Ridgeway J; White R; Jackson C; Djandjighian L; Hedges R; Wireko FC; Ritter AL
Bioorg Med Chem Lett; 2006 Sep; 16(17):4629-32. PubMed ID: 16793267
[TBL] [Abstract][Full Text] [Related]
8. Dynamics and modulation studies of human voltage gated Kv1.5 channel.
Bhuyan R; Seal A
J Biomol Struct Dyn; 2017 Feb; 35(2):380-398. PubMed ID: 26786269
[TBL] [Abstract][Full Text] [Related]
9. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of Kv1.5 channel block by diphenyl phosphine oxide-1.
Du YM; Zhang XX; Tu DN; Zhao N; Liu YJ; Xiao H; Sanguinetti MC; Zou A; Liao YH
J Mol Cell Cardiol; 2010 Jun; 48(6):1111-20. PubMed ID: 20184887
[TBL] [Abstract][Full Text] [Related]
11. Hemitoxin, the first potassium channel toxin from the venom of the Iranian scorpion Hemiscorpius lepturus.
Srairi-Abid N; Shahbazzadeh D; Chatti I; Mlayah-Bellalouna S; Mejdoub H; Borchani L; Benkhalifa R; Akbari A; El Ayeb M
FEBS J; 2008 Sep; 275(18):4641-50. PubMed ID: 18699777
[TBL] [Abstract][Full Text] [Related]
12. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.
Ravens U; Wettwer E
Cardiovasc Res; 2011 Mar; 89(4):776-85. PubMed ID: 21159668
[TBL] [Abstract][Full Text] [Related]
13. Structure-based secondary structure-independent approach to design protein ligands: Application to the design of Kv1.2 potassium channel blockers.
Magis C; Gasparini D; Lecoq A; Le Du MH; Stura E; Charbonnier JB; Mourier G; Boulain JC; Pardo L; Caruana A; Joly A; Lefranc M; Masella M; Menez A; Cuniasse P
J Am Chem Soc; 2006 Dec; 128(50):16190-205. PubMed ID: 17165772
[TBL] [Abstract][Full Text] [Related]
14. Acacetin causes a frequency- and use-dependent blockade of hKv1.5 channels by binding to the S6 domain.
Wu HJ; Wu W; Sun HY; Qin GW; Wang HB; Wang P; Yalamanchili HK; Wang J; Tse HF; Lau CP; Vanhoutte PM; Li GR
J Mol Cell Cardiol; 2011 Dec; 51(6):966-73. PubMed ID: 21906601
[TBL] [Abstract][Full Text] [Related]
15. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
Jackson CM; Blass B; Coburn K; Djandjighian L; Fadayel G; Fluxe AJ; Hodson SJ; Janusz JM; Murawsky M; Ridgeway JM; White RE; Wu S
Bioorg Med Chem Lett; 2007 Jan; 17(1):282-4. PubMed ID: 17095219
[TBL] [Abstract][Full Text] [Related]
16. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
17. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.
Gross MF; Castle NA; Zou A; Wickenden AD; Yu W; Spear KL
Bioorg Med Chem Lett; 2009 Jun; 19(11):3063-6. PubMed ID: 19398199
[TBL] [Abstract][Full Text] [Related]
18. Different residues in channel turret determining the selectivity of ADWX-1 inhibitor peptide between Kv1.1 and Kv1.3 channels.
Yin SJ; Jiang L; Yi H; Han S; Yang DW; Liu ML; Liu H; Cao ZJ; Wu YL; Li WX
J Proteome Res; 2008 Nov; 7(11):4890-7. PubMed ID: 18937510
[TBL] [Abstract][Full Text] [Related]
19. Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.
Gross MF; Beaudoin S; McNaughton-Smith G; Amato GS; Castle NA; Huang C; Zou A; Yu W
Bioorg Med Chem Lett; 2007 May; 17(10):2849-53. PubMed ID: 17350840
[TBL] [Abstract][Full Text] [Related]
20. Structure-based virtual screening and electrophysiological evaluation of new chemotypes of K(v)1.5 channel blockers.
Yang Q; Fedida D; Xu H; Wang B; Du L; Wang X; Li M; You Q
ChemMedChem; 2010 Aug; 5(8):1353-8. PubMed ID: 20540065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
